Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling) [Current Opinion in Pharmacology 2007, 7:219-224] (DOI:10.1016/j.coph.2006.09.006);Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling)

Current Opinion in Pharmacology

Volumn 7, Issue 2, 2007, Pages 219-224

  Goette, Andreas ^a   Bukowska, Alicja ^a   Lendeckel, Uwe ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ASCORBIC ACID; AUTACOID; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FASUDIL; HYDRALAZINE; ION CHANNEL; IRBESARTAN; LOSARTAN; MATRIX METALLOPROTEINASE INHIBITOR; MEPREDNISONE; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROCOLLAGEN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; SPIRONOLACTONE; TACROLIMUS; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VX 702;

CARDIOVERSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DOG; DRUG DOSE REDUCTION; DRUG TARGETING; HEART ARRHYTHMIA; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART SURGERY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INTRACARDIAC THROMBOSIS; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VALVULAR HEART DISEASE; VITAMIN SUPPLEMENTATION;

EID: 33947158718     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.04.002     Document Type: Erratum

References (58)

1. Brand F.N., Abbott R.D., Kannel W.B., and Wolf P.A. Characteristics and prognosis of lone atrial fibrillation: 30 years follow-up in the Framingham Study. J Am Med Assoc 254 (1985) 3449-3453
2. Kannel W.B., Abbott R.D., Savage D.D., and McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306 (1982) 1018-1022
3. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219-226
4. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., and Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects. Am J Cardiol 74 (1994) 236-241
5. Hart R.G., and Halperin J.L. Atrial fibrillation and stroke: concepts and controversies. Stroke 32 (2001) 803-808
6. Azpitarte J., Alvarez M., Baun O., Garcia R., Moreno E., Martin F., Tercedor L., and Fernandez R. Value of single oral loading dose propafenone in converting recent-onset atrial fibrillation: results of a randomized, double-blind, controlled study. Eur Heart J 18 (1997) 1649-1654
7. Lee S.H., Chen S.A., Tai C.T., Chiang C.E., Wen Z.C., Chen Y.J., Yu W.C., Huang J.L., Fong A.N., Cheng J.J., and Chang M.S. Comparison of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 79 (1997) 905-908
8. Chun S.H., Sager P.T., Stevenson W.G., Nademanee K., Middlekauff H.R., and Singh B.N. Long-term efficacy of amiodarone for maintenance of normal sinus rhythm in patients with refractory atrial fibrillation and flutter. Am J Cardiol 76 (1995) 47-50
9. Ausma J., Wijffels M., Thone F., Wouters L., Allessie M., and Borgers M. Structural Changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96 (1997) 3157-3163
10. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
11. Goette A., Juenemann G., Peters B., Klein H.U., Roessner A., Huth C., and Röcken C. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovasc Res 54 (2002) 390-396
12. Ausma J., Dispersyn G.D., Duimel H., Thone F., Ver Donck L., Allessie M.A., and Borgers M. Changes in ultrastructural calcium distribution in goat atria during atrial fibrillation. J Mol Cell Cardiol 32 (2000) 355-364
13. 2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 110 (2004) 2651-2657
14. Goette A., Staack T., Arndt M., Röcken C., Geller C., Huth C., Ansorge S., Klein H.U., and Lendeckel U. Increased expression of extracellular-signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35 (2000) 1669-1677
15. Röcken C., Peters B., Juenemann G., Saeger W., Klein H.U., Huth C., Roessner A., and Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 106 (2002) 2091-2097
16. Li D., Fareh S., Leung T.K., and Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100 (1999) 87-95
17. Urata H., Healy B., Stewart R.W., Bumpus F.M., and Husain A. Angiotensin II-forming pathways in normal and failing hearts. Circ Res 66 (1990) 883-890
18. Sugden P.H., and Clerk A. Regulation of the ERK subgroup of MAP kinase cascade through G protein-coupled receptors. Cell Signal 9 (1997) 337-351
19. Goette A., Arndt M., Röcken C., Staack T., Geller J.C., Huth C., Ansorge S., Klein H.U., and Lendeckel U. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 101 (2000) 2678-2681
20. Li D., Shinagawa K., Pang L., Leung T.K., Cardin S., Wang Z., and Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001) 2608-2614
21. Shirani J., and Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol 9 (2000) 95-101
22. Aime-Sempe C., Folliguet T., Rucker-Martin C., Krajewska M., Krajewska S., Heimburger M., Aubier M., Mercadier J.J., Reed J.C., and Hatem S.N. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 34 (1999) 1577-1586
23. Lendeckel U., Arndt M., Wrenger S., Nepple K., Huth C., Ansorge S., Klein H.U., and Goette A. Expression and activity of ectopeptidases in fibrillating human atria. J Mol Cell Cardiol 33 (2001) 1273-1281
24. Dudley S.C., Hoch N.E., McCann L.A., Honeycutt C., Diamandopoulos L., Fukai T., Harrison D.G., Dikalov S., and Langberg J.J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage. Role of the NADPH and xanthine oxidase. Circulation 112 (2005) 1266-1273. This study is the first to demonstrate increased activity of atrial NADPH in atrial fibrillation.
25. Goette A., Hoffmanns P., Enayati W., Maltendorf U., Geller J.C., and Klein H.U. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 88 (2001) 906-909
26. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., and Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41 (2003) 2197-2204
27. Boldt A., Scholl A., Garbade J., Resetar M.E., Mohr F.W., Gummert J.F., and Dhein S. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 101 (2006) 261-267
28. Neuberger H.R., Schotten U., Blaauw Y., Vollmann D., Eijsbouts S., vanHunnik A., and Allessie M. Chronic atrial dilation, electrical remodeling and atrial fibrillation in the goat. J Am Coll Cardiol 47 (2006) 644-653. This is the first systematic study that analyses the pathophysiologic interaction between chronic atrial dilation, atrial stretch and pro-arrhythmogenic electrophysiologic alterations.
29. Okazaki H., Minamino T., Tsukamoto O., Kim J., Okada K., Myoishi M., Wakeno M., Takashima S., Mochizuki N., and Kitakazae M. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens Res 29 (2006) 277-284. This experimental study demonstrated that chronic inhibition of NO synthesis increases the extent of fibrosis and transforming growth factor-β expression in atrial tissue. Furthermore, the authors demonstrate that both of these effects can be prevented by candesartan.
30. Spach M.S., Heidlage J.F., Dolber P.C., and Barr R.C. Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junctions and Na(+) channels. J Electrocardiol 34 Suppl (2001) 69-76
31. Dagres N., Karatasakis G., Panou F., Athanassopoulos G., Maounis T., Tsougos E., Kourea K., Malakos I., Kremastinos D.T., and Cokkinos D.V. Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation. Eur Heart J 27 (2006) 2062-2068
32. Ehrlich J.R., Hohnloser S.H., and Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27 (2006) 512-518. This is an excellent review of experimental and clinical results about angiotensin II and atrial fibrillation.
33. Zannad F., Alla F., Dousset B., Perez A., and Pitt B. Limitation of excessive axtracellualr matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomised aldactone evaluation study (RALES). Circulation 102 (2000) 2700-2706
34. Milliez P., DeAngelis N., Rucker-Martin C., Leenhardt A., Vicaut E., Robidel E., Beaufils P., Delcayre C., and Hatem S.N. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26 (2005) 2193-2199
35. Boldt A., Wetzel U., Lauschke J., Weigel J., Gummert J., Hindricks G., Kottkamp H., and Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90 (2004) 400-405
36. Goette A., Röcken C., Nepple K., and Lendeckel U. Proteases and Arrhythmias. In: Lendeckel U., and Hooper N.M. (Eds). Proteases in Biology and Disease: Proteases in Tissue Remodelling of Lung and Heart (2003), Kluwer Academic, Plenum Publishers 191-218
37. Marin F., Roldan V., Climent V., Garcia A., Marco P., and Lip G.Y.H. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and ist inhibitor, TIMP-1?. Stroke 34 (2003) 1181-1186
38. Xu J., Cui G., Esmailian F., Plunkett M., Marelli D., Ardehali A., Odim J., Laks H., and Sen L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 (2004) 363-368
39. Corradi D., Callegari S., Benussi S., Nascimbene S., Pastori P., Calvi S., Maestri R., Astorri E., Pappone C., and Alfieri O. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch 445 (2004) 498-505
40. Anne W., Willems R., Roskams T., Sergeant P., Herijgers P., Holemans P., Ector H., and Heidbüchel H. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 67 (2005) 655-666
41. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 108 (2003) 1395-1403
42. Zhao B.Q., Wang S., Kim H.Y., Storrie H., Rosen B.R., Mooney D.J., Wang X., and Lo E.H. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12 (2006) 441-445. This paper is a very important study showing time-dependent differences in MMP effects after cerebral ischemia.
43. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., Van Wagoner D.R., and Bauer J.A. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104 (2001) 174-180
44. Carnes C.A., Chung M.K., Nakayama T., Nakayama H., Baliga R.S., Piao S., Kanderian A., Pavia S., Hamlin R.L., McCarthy P.M., et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89 (2001) e32-e38
45. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
46. Jones S.P., Teshima Y., Akao M., and Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 93 (2003) 697-699
47. Bukowska A., Lendeckel U., Hirte D., Wolke C., Striggow F., Rohnert P., Huth C., Klein H.U., and Goette A. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. J Cell Mol Life Sci 63 (2006) 333-342. This is the first study using an organotypic human atrial tissue culture model to determine tachycardia-induced molecular effects in vitro.
48. Molkentin J.D. Calcineurin and beyond. Cardiac hypertrophic signaling. Circ Res 87 (2000) 731-738
49. Lim H.W., DeWindt L.J., Steinberg L., Taigen T., Witt S.A., Kimball T.R., and Molkentin J.D. Calcineurin expression, activation and function in cardiac pressure-overload hypertrophy. Circulation 101 (2000) 2431-2437
50. Haines D.D., Bak I., Ferdinandy P., Mahmoud F.F., Al-Harbi S.A., Blasig I.E., and Tosaki A. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, Egb 761, in isolated ischemic/reperfused rat hearts. J Cardiovasc Pharmacol 35 (2000) 37-44
51. Engelmann M.D.M., and Svendson J.H. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26 (2005) 2083-2092. This is an excellent review summarizing the interaction between inflammatory processes and atrial fibrillation.
52. Goette A., Arndt M., Röcken C., Staack T., Bechtloff R., Reinhold R., Huth C., Ansorge S., Klein H.U., and Lendeckel U. Calpains and cytokines in fibrillating human atria. Am J Physiol Heart Circ Physiol 283 (2002) H264-H272
53. Dernellis J., and Panaretou M. Relationship between C-reactive protein concentration during glococorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25 (2004) 110-1107
54. Yared J.P., Starr N.J., Torres F.K., Bashour C.A., Bourdakos G., Piedmonte M., Michener J.A., Davis J.A., and Rosenberger T.E. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann Thorac Surg 69 (2000) 1420-1424
55. Shiroshita-Takeshita A., Brundel B.J., Lavoie J., and Nattel J. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 69 (2006) 865-875
56. Anderson M.E., Higgins L.S., and Schulman H. Disease mechanims and emerging therapies: protein kinases and their inhibitors in myocardial disease. Nat Clin Pract Cardiovasc Med 3 (2006) 437-445. This review paper summarizes in detail the potential role of protein kinases in myocardial diseases.
57. 2+ handling in AF is associated with impaired phosphorylation of myosin binding protein C, which might contribute to the contractile dysfunction after cardioversion. Thus, the study is the first to suggest that restoration of sarcoplasmic reticulum-associated phosphatase function may represent a new therapeutic option for treatment of AF.
58. Tessier S., Karczewski P., Krause E.G., Pansard Y., Acar C., Lazdunski M.L., Mercadier J.J., and Hatem S.N. Regulation of the transient outward current K+ current by calcium/calmodulin-dependent protein kinase II in human atrial myocytes. Circ Res 85 (1999) 810-819